Sign in
Taking people in United KingdomNo phase

Heart map guided treatment for ventricular tachycardia, a dangerous fast heart rhythm

Tests VIVO mapping to guide catheter ablation in people with ventricular tachycardia.

Key facts

Who runs it
University of Warwick
Where
Brighton, Coventry, and Middlesbrough, United KingdomSee the 3 sites
Trial code
Registry title
Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia
Status
Recruiting
People taking part
110 people, planned
Started
15 Aug 2026
Expected to end
29 Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • VIVO-assisted mapping
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with ventricular tachycardia (a dangerous fast heart rhythm) after a past heart attack. Everyone will have catheter ablation, guided either by the VIVO map or by the standard method.

Age
18 years or older
Sex
All sexes
Disease stage
Heart damage from a past heart attack, with VT treated by an implanted device: at least 1 appropriate ICD shock or 3 ATP episodes within a 6-month period. People must be able to have VT ablation under NHS standard of care.
Earlier treatment
Must have an implanted ICD or CRTD device. Must have had a cardiac CT and/or cardiac MRI scan within 6 months.

Main reasons for not taking part

  • Blood clot, tumour or other problem in the heart or vessels that blocks catheter use
  • Bleeding or clotting disorders
  • Infection, sepsis or fever (>100.5 F/38 C) in the week before the procedure
  • Kidney failure needing dialysis, or serious kidney problems
  • Pregnant or breastfeeding; allergy to contrast dye

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • ≥18 years old
  • Patient with the following:; Evidence of post-myocardial infarction* structural heart disease; Cardiac CT and/or cardiac MRI scan performed within 6 months; ICD/CRTD implantation; Device therapy for VT: at least 1 appropriate ICD shock or 3 ATP episodes within a 6-month period
  • Suitable candidate for VT ablation as per NHS standard of care
  • Patient agrees to comply with study procedures and be available for routine follow up visits for at least 6 months after enrolment

Who cannot take part

  • Sepsis, active systemic infection or fever (>100.5 F/38 C) within a week prior to the ablation procedure
  • Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem them inappropriate to participate in this study
  • Coagulopathy, bleeding diathesis or suspected pro-coagulant state
  • Renal failure requiring dialysis or renal compromise that in the investigator's judgement would increase risk to the patient or deem the patient inappropriate to participate in the study
  • Known allergies or intolerance to AADs to be used to treat PVCs
  • Known allergy for contrast
  • Other conditions that may prevent patients from adhering to the study protocol, in the opinion of the investigator
  • Lacks capacity to provide informed consent
  • Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations
  • Female patients who are pregnant or breast feeding

Where in United Kingdom

  • Royal Sussex County HospitalBrighton, United KingdomContact: John Silberbauer, Dr.Not yet recruiting
  • University Hospitals Coventry and WarwickshireCoventry, United KingdomContact: Tarv Dhanjal, Dr.Taking people
  • The James Cook University HospitalMiddlesbrough, United KingdomContact: Matthew Bates, Dr.Taking people

About the trial

What the trial wants to find out

Ventricular tachycardia (VT) is an abnormal and dangerous heart rhythm affecting the lower chambers of the heart (the ventricles). Patients with structural heart disease caused by previous heart attacks are at an increased risk of developing VT. Current guidelines recommend that patients who develop this abnormal heart rhythm are considered for invasive catheter ablation (ICA). This is an invasive procedure where specialised catheters and a 3D electro anatomical mapping (EAM) system are used to identify the region of the heart responsible for the VT, which is then treated by tissue heating or freezing (ablation). Although significant improvements have been made in both mapping and ablation technologies, these procedures remain technically challenging and time consuming.

Read full original descriptionShow less

View into ventricular onset (VIVO, Catheter Precision) is a non-invasive, mapping system already being used within the NHS. It uses images from previous heart scans, a picture of the patient's chest (taken at the start of the procedure) and a 12-lead electrocardiogram (ECG) tracing, to locate where the VT is coming from. The VIVO map can therefore highlight the likely region of interest for ICA prior to invasive EAM.

This study will be a prospective, multi-centre, two-arm, non-blinded, randomised controlled trial (RCT). Patients will be evenly randomised (50:50) into a standard VT ablation group and a VIVO guided ablation group. In the VIVO guided ablation group, invasive EAM will be restricted to the region of interest identified using the VIVO map, rather than whole chamber mapping required for standard ablation. The primary objective will be to determine if the VIVO non-invasive mapping system reduces procedure duration and therefore improves workflow efficiency. Secondary objectives will assess the procedural success, safety and patient perceived health benefits of a VIVO guided ablation versus standard ablation.

The 2 groups in the trial

  • VIVO-assisted VT ablationExisting treatment, for comparison

    Treatment: VIVO-assisted mapping

  • Standard VT AblationNo study treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia: a UK Randomised Controlled Trial
Plain-language title
Heart map guided treatment for ventricular tachycardia, a dangerous fast heart rhythmGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
12 August 2026